Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

us recorded revenue during the first quarter of 2008 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the first quarter 2008, Amicus recognized $0.7 million of the Shire upfront payment and $2.5 million of research revenue on reimbursed research and development costs.

Amicus today reiterated its guidance for 2008 cash burn of $40 million to $60 million. The Company also stated that it does not expect to raise cash from any equity financings in 2008.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in tables 2 and 3, and are primarily due to:

-- Pre-tax stock compensation expense

-- Pre-tax charges for preferred stock accretion

-- Pre-tax charges for changes in the fair value of warrant liability

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per

common share exclude the impact of the stock option expense recorded

in accordance with
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
(Date:7/1/2015)...  UCB, a multinational biopharmaceutical company, and Genpact ... designing, transforming, and running intelligent business operations, have ... their close collaboration in driving transformation that achieved ... (GBS) finance organization. The Aecus Innovation ... together effectively to embrace the innovative promise of ...
(Date:6/30/2015)... Clara CA (PRWEB) , ... June 30, 2015 ... ... microscopy (AFM) is hosting a webinar to provide advanced scientific research into new ... science, bio science and energy. Touted as 'the wonder material of the ...
(Date:6/30/2015)... San Francisco, CA (PRWEB) , ... June 30, ... ... in FMT Patients , Study will provide new insights on mechanics of fecal ... announced a new partnership to study the microbiome of patients undergoing fecal microbiota ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... , ATLANTA and LONDON, Sept. 10 ... ) an implantable biological medical device and cardiovascular tissue processing company, ... (R) Surgical Matrix, which received CE mark approval in August ... removal as a supplemental measure to promote hemostasis (a complex process ...
... Md., Sept. 10 DHA omega-3 innovator and maker of the ... ), announced today it has resolved a patent dispute with Capsugel ... in the High Court of Strasbourg, France. , , ... Capsugel France, Capsugel and all of its affiliates have agreed to ...
... Texas, Sept. 10 , , WHO: Panel of leading ... WHEN: Tuesday, September 15th , , 9:50 a.m. ... on eDiscovery for Pharma, Biotech & Medical Device Industries , , ... TOPIC: Cost-Benefit Analysis of In-house eDiscovery Tools vs. Outsourcing Help , , ...
Cached Biology Technology:CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5Martek Announces Settlement of Patent Dispute with Capsugel France 2StoredIQ Shares Expertise at IQPC's eDiscovery Pharma, Biotech and Medical Device Conference 2
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... damage depends on the balance between the generation of scar ... significant minority of people who get injury to their organs ... to chronic liver disease and cirrhosis where the scarring is ... produce vital hormones and clotting factors. Liver scars also provide ...
... Barbara, Calif.) The National Institutes of Health (NIH) ... engineering, chemistry, and biology researchers to develop a highly ... The technology provides an entirely new method of discovering ... range of applications, including next-generation disease diagnosis at the ...
... (HGNS) produced marked dose-related increases in airflow in obstructive ... according to a new study from the Johns Hopkins ... efficacy of HGNS across a broad range of sleep ... airway pressure (CPAP), the current mainstay of treatment for ...
Cached Biology News:Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology 2Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology 3Hypoglossal nerve stimulation increases airflow during sleep in obstructive sleep apnea 2
... you to store and manage very large ... secure central relational database. Storing and managing ... resource for clone tracking and enables you ... analysis. LabShare software integrates seamlessly with Invitrogen's ...
... A and Protein G bind specifically to ... A and Protein G conjugates are commonly ... (antibodies) and immunoglobulin subtypes from serum, hybridoma ... biological fluids. These reagents are also commonly ...
... many of the automation concepts from High ... are similar to those for HTS: ... or 48 wells with well volumes of ... number of wells has increased to 96 ...
... for 0.2ml thermal cycler blocks, 96-well PCR plate, ... and heat seals), Cut-away corner , Fits all ... and 3700 capillary sequencers, Clear well bottom for ... Thermo-Mats, Adhesive Films and Foils, Heat Seals and ...
Biology Products: